Collaborations - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended			12 Months Ended
	Jul. 07, 2020	May 09, 2019	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023	Dec. 31, 2023
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Unsatisfied performance obligation			$ 42,600
Cost reimbursement payment received			3,800
Unbilled accounts receivable			2,000
Research and development			$ 48,819		$ 42,227
Remaining research term of collaboration			2 years 9 months 18 days
Revenue recognized			$ 10,287		9,466
Deferred Revenue			12,400
Revenue Recognized			55,000
Milestone Two [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized recorded in deferred revenue			2,300
Unconstrained Consideration				$ 55,000		$ 55,000
Sanofi Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment	$ 150,000
Collaboration agreement transaction price	150,000
Revenue recognized recorded in deferred revenue			10,300		7,700
Unsatisfied performance obligation			46,400	54,700		54,700
Milestone receivable			15,000
Revenue recognized			10,300			8,700
Sanofi Agreement | Milestone One [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration revenue recognised				40,000
Sanofi Agreement | Milestone Two [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration revenue recognised				15,000
Sanofi Agreement | Collaboration Target 1
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement transaction price	120,000
Revenue recognized recorded in deferred revenue					7,100
Sanofi Agreement | Collaboration Target 2
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement transaction price	30,000
Revenue recognized recorded in deferred revenue					600
Sanofi Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development milestone payments	1,480,000
Commercial Milestone Payments	700,000
Sanofi Agreement | Minimum | IRAK4 Program
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development milestone payments	1,000,000
Commercial Milestone Payments	$ 400,000
Vertex Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized recorded in deferred revenue					1,800
Unsatisfied performance obligation			$ 0	$ 0		$ 0
Initial research term of collaboration		4 years
Extended research term of collaboration		1 year
Revenue recognized					$ 1,800
Vertex Agreement | Series B-1 Preferred Stock
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement transaction price		$ 55,900
Non refundable upfront payment received		$ 50,000
Issuance of shares, Shares		3,059,695
Stock issued price per share		$ 6.54
Preferred stock premium		$ 5,900
Vertex Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Eligible to receive payments including development, regulatory and commercial milestones		$ 170,000